IP Library Granted Patent US 11,590,265
Granted Patent B2
US 11,590,265 · App. 16/591,219 · Granted Feb 28, 2023

Apparatuses and methods for treating ophthalmic diseases and disorders

Inventors: Scheffer Tseng (Pinecrest, FL); Ek Kia Tan (Miami, FL)
Assignee: BIOTISSUE HOLDINGS INC.
A61L31/005A61F9/0017A61L31/146A61L31/16A61L2300/406A61L2430/16A61N1/0452A61N1/36003
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,590,265
App. No.
16/591,219
Granted
Feb 28, 2023
Kind
B2
Abstract

The invention relates generally to the fields of biology and health sciences. More particularly, the invention relates to compositions and methods for modulating cellular physiology and pathological processing using a combination of compounds that can be found in amniotic membrane tissue and umbilical cord tissue preparations.

Claims (18)

1. An apparatus for treating a disease or disorder of an eye of an individual in need thereof, the apparatus comprising:

(a) an annular tubular structure comprising at least one porous outlet; and wherein the apparatus is configured to reside in a superior conjunctiva fornix, an inferior fornix, or a combination thereof, and to deepen the fornix tear reservoir by stretching the conjunctival sac; and

(b) a therapeutic agent encapsulated by the tubular structure, the therapeutic agent comprising umbilical cord tissue, amniotic membrane tissue, placental tissue, chorion tissue, or a combination thereof.

2. The apparatus of claim 1 , wherein the therapeutic agent comprises amniotic membrane tissue, umbilical cord tissue, or a combination thereof.

3. The apparatus of claim 2 , wherein the therapeutic agent comprises morselized amniotic membrane, or morselized umbilical cord.

4. The apparatus of claim 1 , wherein the annular tubular structure is a tubular structure comprising ethylene vinyl acetate (EVA), polydimethylsiloxane (PDMS), polymethylmetacrylate (PMMA), polyethylene teraphthalate (PET), fibrins, polycarbonate (PC), hydrogels, polyvinyl chloride (PVC), rubber, latex, polyethylene (PE), silicone, polytetrafluoroethylene (PTFE), polyurethane (PU), or a combination thereof.

5. The apparatus of claim 1 , wherein the annular tubular structure has an outside diameter of about 0.5 (centimeters) cm to about 5.0 cm.

6. The apparatus of claim 1 , wherein the annular tubular structure has a cross-sectional diameter of about 0.01 cm to 1 cm.

7. The apparatus of claim 1 , wherein the annular tubular structure has a cross-sectional diameter of about 0.05 cm to 1 cm and an outside diameter of about 2.6 cm to 2.8 cm.

8. The apparatus of claim 1 , wherein the annular tubular structure has a cross-sectional diameter of about 0.1 cm and an outside diameter of about 2.7 cm.

9. The apparatus of claim 1 , wherein the annular tubular structure has at least one porous inlet.

10. The apparatus of claim 1 , wherein the therapeutic agent further comprises an excipient.

11. The apparatus of claim 10 , wherein the excipient comprises a stabilizing agent, a surfactant, a chelating agent, or a combination thereof.

12. A method for treating a disease or disorder of an eye of an individual in need thereof, comprising inserting the apparatus of claim 1 onto the surface of an eye of the individual.

13. The apparatus of claim 1 , wherein the annular tubular structure comprises at least one porous inlet and at least one porous outlet.

14. The apparatus of claim 13 , wherein the at least one porous inlet and the at least one porous outlet form an osmotic pump when in contact with tears in the individual's eye.

15. The apparatus of claim 1 , wherein the annular tubular structure is configured to dissolve when in contact with the tears in the individual's eye.

16. The apparatus of claim 1 , wherein the therapeutic agent is present in a form selected from the group consisting of lyophilized, fresh, sheet, morselized, powder matrix, extract, purified extract, previously frozen, and a suspension.

Assignments (5)
SECURITY INTEREST Recorded Jun 7, 2024
From: BIOTISSUE HOLDINGS INC.; BIOTISSUE OCULAR INC.; BIOTISSUE SURGICAL INC.
To: U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION
Reel/Frame 067666/0235 →
CHANGE OF NAME Recorded May 10, 2023
From: TISSUETECH, INC.
To: BIOTISSUE HOLDINGS INC.
Reel/Frame 063591/0802 →
CHANGE OF NAME Recorded Jan 18, 2023
From: TISSUETECH, INC.
To: BIOTISSUE HOLDINGS INC.
Reel/Frame 063802/0276 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 21, 2022
From: TSENG, SCHEFFER
To: TISSUETECH, INC.
Reel/Frame 060266/0252 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 21, 2022
From: TAN, EK KIA
To: TISSUETECH, INC.
Reel/Frame 060266/0304 →
Continuity (3)
Continuation 15051477 · Feb 23, 2016
Provisional Application 62119544 · Feb 23, 2015
Related Publication 20200061250A1 · Feb 27, 2020
Cited By (3)
US 12,508,349 US 12,551,510 US 12,558,379